Analysis Tools
digestive/alimentary system
|
• in the ileum of DSS-treated mice exacerbated by IL22 treatment
• however, co-treatment with anti-IFNAR antibodies reduces the crypt region cell death under hard DSS treatment plus IL22
• organoid cell death induced by IFNbeta is amplified
|
|
• under a harsh DSS treatment regime, mice exhibit increased inflammatory regardless of anti-IFNAR treatment compared with control mice
• however, severity of colonic inflammation is not exacerbated by IL22 treatment
|
|
• under mild or harsh DSS treatment regimes, mice exhibit increased ileal inflammation exacerbated by IL22 treatment compared with control mice
• however, co-treatment with anti-IFNAR antibodies reduces the severity of small intestinal inflammation under hard DSS treatment plus IL22
|
growth/size/body
|
• in mice treated with IL22 and DSS
|
immune system
|
• under a harsh DSS treatment regime, mice exhibit increased inflammatory regardless of anti-IFNAR treatment compared with control mice
• however, severity of colonic inflammation is not exacerbated by IL22 treatment
|
|
• under mild or harsh DSS treatment regimes, mice exhibit increased ileal inflammation exacerbated by IL22 treatment compared with control mice
• however, co-treatment with anti-IFNAR antibodies reduces the severity of small intestinal inflammation under hard DSS treatment plus IL22
|
cellular
|
• in the ileum of DSS-treated mice exacerbated by IL22 treatment
• however, co-treatment with anti-IFNAR antibodies reduces the crypt region cell death under hard DSS treatment plus IL22
• organoid cell death induced by IFNbeta is amplified
|
